TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12505808
Drug: 1% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% testosterone gel, 10 g/day
Study: 9856366
Drug: Captopril at
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril at 50 mg twice a day
Study: 1694945
Drug: Xamoterol 200
Normalized name: xamoterol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol 200 mg twice daily for 13 weeks
Study: 1694945
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 13 weeks
Study: 1694945
Drug: Xamoterol 200
Normalized name: xamoterol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol 200 mg
Study: 41475
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg i.v. dose of labetalol
Study: 41475
Drug: 2.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg/kg i.v. dose of labetalol
Study: 27997257
Drug: Carbohydrate gel
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate gel
Study: 22462237
Drug: High-frequency electric
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency electric sparkle and point-injection therapy (HESPT)
Study: 22462237
Drug: Point-injection therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point-injection therapy
Study: 11730179
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 110, 220, 330, and 440 microg, twice daily
Study: 11730179
Drug: Flunisolide 500
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flunisolide 500 and 1,000 microg, twice daily
Study: 11730179
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone 7.5 mg daily
Study: 9155405
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment for diarrhea
Study: 31857300
Drug: Nasal high-flow
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high-flow (NHF) therapy
Study: 12787319
Drug: Small molecule
Normalized name: Small molecule melanocortin 4 receptor agonist
DrugBank: LB54640 (DB18331)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small molecule mimetics
Study: 10918646
Drug: Loop diuretic
Normalized name: Loop diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop diuretic therapy
Study: 10918646
Drug: Early intravenous
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intravenous beta blockade
Study: 10918646
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers or magnesium
Study: 1640282
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three vaccines (PRP‐OMP, PRP‐T, HbOC)
Study: 6725168
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group ($5.00 for providing a specimen twice weekly)
Study: 24582119
Drug: fesoterodine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: fesoterodine (8 mg)
Study: 24582119
Drug: tolterodine extended‐release
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine extended‐release (4 mg)
Study: 22086749
Drug: First Generation
Normalized name: First generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: First Generation Antipsychotics (FGAs) - Haloperidol or Trifluoperazine
Study: 8092094
Drug: Moderately protein‐restricted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately protein‐restricted diet (0.8 g.kg body wt‐1.d‐1)
Study: 8092094
Drug: Unrestricted protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unrestricted protein diet (> 1.6 g.kg body wt‐1.d‐1)
Study: 2679238
Drug: Cimetidine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 7.5 mg/kg (group 1)
Study: 2679238
Drug: Ranitidine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 1.5 mg/kg (group 2)
Study: 2679238
Drug: Ranitidine 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 2.0 mg/kg (group 3)
Study: 1189983
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg vitamin K1 (Konakion) administered intravenously
Study: 1189983
Drug: Warfarin (Marevan)
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin (Marevan)
Study: 1189983
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg vitamin K1 (Konakion)
Study: 25675062
Drug: Lumbar interlaminar
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lumbar interlaminar epidural injections of local anesthetic (lidocaine 0.5%) 6 mL
Study: 25675062
Drug: Lumbar interlaminar
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lumbar interlaminar epidural injections with local anesthetic (lidocaine 0.5%) 5 mL mixed with 1 mL of steroids and 6 mg of betamethasone
Study: 25675062
Drug: Successful group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful group of lumbar interlaminar epidural injections of local anesthetic (lidocaine 0.5%) 6 mL
Study: 25675062
Drug: Successful group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful group of lumbar interlaminar epidural injections with local anesthetic (lidocaine 0.5%) 5 mL mixed with 1 mL of steroids and 6 mg of betamethasone
Study: 24056293
Drug: AT substitution
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT substitution in children with AT activity below 0.55 kIU/l (n = 36)
Study: 24056293
Drug: Prolonged continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged continuous ASP treatment
Study: 22448235
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg/d for 18 months
Study: 19110158
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein greater than 3.2 mg/dL
Study: 19110158
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ulcer depth and C-reactive protein
Study: 19110158
Drug: Ulcer depth
Normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ulcer depth greater than 3 mm or C-reactive protein greater than 3.2 mg/dL
Study: 17227995
Drug: Regimen-DI (intensified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen-DI (intensified treatment with six 2-week cycles of cisplatin [100 mg/m2 by 24-hour infusion] and doxorubicin [25 mg/m2/day by 4-hour infusion for 3 days])
Study: 17227995
Drug: Regimen-C (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen-C (conventional treatment with six 3-week cycles of cisplatin [100 mg/m2 by 24-hour infusion] and doxorubicin [25 mg/m2/day by 4-hour infusion for 3 days])
Study: 9736420
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) (enoxaparin, 1.5 mg/kg/day) subcutaneously (sc) once daily for 72 hours
Study: 9736420
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) (initial infusion rate 450 IU/kg/day) continuous intravenous (iv) for 72 hours
Study: 779390
Drug: Atropine 0.01
Normalized name: atropine 0.0194 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.01 mg/kg body weight given intramuscularly 1 hour before anaesthesia
Study: 779390
Drug: Atropine 0.01
Normalized name: atropine 0.0194 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.01 mg/kg body weight given intravenously 5 minutes prior to induction
Study: 779390
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intramuscular and intravenous atropine in the above-mentioned doses
Study: 779390
Drug: Atropine 0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.015 mg/kg body weight intravenously 5 minutes prior to induction
Study: 779390
Drug: Large doses
Normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large doses of atropine
Study: 779390
Drug: Preoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative administration of atropine
Study: 21374929
Drug: 35 microg
Normalized name: Ethinyl estradiol 35 microgram and norethindrone 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 microg ethinylestradiol (EE) with 2.0 mg cyproterone acetate/day
Study: 21374929
Drug: 30 microg
Normalized name: Levonorgestrel 30 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 microg ethinylestradiol (EE) with 2.0 mg dienogest/day
Study: 21374929
Drug: 30 microg
Normalized name: Levonorgestrel 30 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 microg ethinylestradiol (EE) with 3.0 mg drospirenone/day
Study: 18037776
Drug: losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan (50 mg/day)/HCTZ (12.5 mg/day)
Study: 18037776
Drug: candesartan (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: candesartan (8 mg/day)/amlodipine (5 mg/day)
Study: 10471591
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg of levofloxacin once daily for 14 days
Study: 10471591
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg of levofloxacin three times weekly for 14 days
Study: 10471591
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 14 days
Study: 10471591
Drug: Placebo three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times weekly for 14 days
Study: 2116819
Drug: pirenzepine 50
Normalized name: pirenzepine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pirenzepine 50 mg bd
Study: 24187901
Drug: Calcium supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplement plus low-dose aspirin (500 mg carbonate calcium plus 80 mg aspirin)
Study: 19815692
Drug: Cancer treatment
Normalized name: Retinoids for cancer treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer treatment
Study: 16326339
Drug: 0.1% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% levobupivacaine infusion
Study: 12191747
Drug: Lisinopril 5
Normalized name: lisinopril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 5 mg o.d.
Study: 9790371
Drug: Methylprednisolone, 16
Normalized name: MethylPREDNISolone, 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone, 16 mg 3 times daily, tapered over 2 weeks
Study: 9790371
Drug: Promethazine, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine, 25 mg 3 times daily, continued for 2 weeks
Study: 1978477
Drug: Remoxipride (90-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride (90-600 mg daily)
Study: 1978477
Drug: Haloperidol (5-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (5-45 mg daily)
Study: 26658434
Drug: Uphill sprint
Normalized name: norgestimate
DrugBank: Norgestimate (DB00957)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uphill sprint training (UST) - 10 x 10 sec sprints with 60s recovery on a 7% gradient for six weeks, twice weekly
Study: 19638366
Drug: Aggressive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive blood pressure lowering targeting SBP <130 mmHg using a combination of amlodipine/valsartan and additional antihypertensive medications as needed.
Study: 19638366
Drug: Standard blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard blood pressure lowering targeting SBP <140 mmHg using a combination of amlodipine/valsartan and additional antihypertensive medications as needed.
Study: 19352059
Drug: 1.5 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/d MK-4 for 4 weeks
Study: 12469001
Drug: Tetrabenazine (TBZ)
Normalized name: Tetrabenazine
DrugBank: Tetrabenazine (DB04844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetrabenazine (TBZ) at a final mean dose of 62.5 ± 37.4 mg/day (range 25‐150)
Study: 9469353
Drug: Intensified chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified chemotherapy (V-ICE every 3 weeks)
Study: 9469353
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (V-ICE every 4 weeks)
Study: 9469353
Drug: Granulocyte-macrophage colony-stimulating
Normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF) 250 microg/m2/d for 14 days between chemotherapy cycles
Study: 2229451
Drug: Ciprofloxacin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (750 mg every 12 hours for 5 days before and 24 hours after quinidine administration)
Study: 2229451
Drug: Quinidine sulfate
Normalized name: Quinidine Sulfate
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinidine sulfate (400 mg administered alone)
Study: 361794
Drug: Prednisone 30
Normalized name: prednisone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 30 mg daily
Study: 12577250
Drug: Intravenous amifostine
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous amifostine
Study: 31819309
Drug: Protein supplementation
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplementation and fortification of breast milk (FMS-Aptamil-DANON) during NICU hospitalization, with protein added when milk reached 100 cc/kg/day, increased by 20 cc/kg/day until 150-180 cc/kg/day, stopped when weight reached 1500 grams.
Study: 24691852
Drug: Topical 0.5
Normalized name: phenol topical 0.5% topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.5 % bupivacaine hydrochloride
Study: 24691852
Drug: Topical 0.9
Normalized name: iodine topical 0.9% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.9 % NaCl (saline)
Study: 12383289
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of piroxicam and dexamethasone
Study: 30701349
Drug: Psychosexual counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosexual counseling (6 weekly sessions, 90 to 120 min each)
Study: 17320962
Drug: Vitamin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin therapy (antioxidants plus zinc)
Study: 17320962
Drug: No vitamin
Normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No vitamin therapy
Study: 11179081
Drug: Oral methionine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methionine loading
Study: 9735650
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment without drainage
Study: 9735650
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment with tube drainage
Study: 3395914
Drug: Diltiazem 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 2.0 mg given every 6 h
Study: 23443254
Drug: Anastrozole treatment
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole treatment in compliant patients
Study: 23443254
Drug: Anastrozole treatment
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole treatment in non-compliant patients
Study: 19951540
Drug: Negative-pressure wound
Normalized name: Microcyn Negative-Pressure Wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative-pressure wound therapy (NPWT) with interrupted suction under a pressure of -16.63 kPa for 24 hours or continuous suction under a pressure of -10.64 kPa for 24 hours.
Study: 19951540
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (CT) with petrolatum gauze overlaid with isotonic saline gauze and dry gauze.
Study: 9109903
Drug: Clozapine (39
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (39 mg/day)
Study: 9109903
Drug: Benztropine (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benztropine (3.0 mg/day)
Study: 3281872
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth (120 mg administered through an intraoesophageal tube four times a day) + Cimetidine (800 mg at night)
Study: 3281872
Drug: Cimetidine alone
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine alone (800 mg at night)
Study: 25915944
Drug: PET/CT-guided dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET/CT-guided dose escalation chemoradiotherapy (group C)
Study: 25915944
Drug: CT-guided dose
Normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-guided dose escalation chemoradiotherapy (group B)
Study: 19785620
Drug: Pharmaceutical company
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical company sponsorship
Study: 12105323
Drug: Topiramate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (400 mg/d or maximum tolerated dose)
Study: 16362532
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg methylprednisolone injection
Study: 16362532
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg methylprednisolone injection
Study: 16362532
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg methylprednisolone injection
Study: 16362532
Drug: One or
Normalized name: Geone Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: One or two injections of methylprednisolone
Study: 16362532
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (20 mg, 40 mg, 60 mg)
Study: 11914933
Drug: UFT (uracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (uracil and tegafur) administered at 400 mg/day for 2 years
Study: 10885606
Drug: Docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg/m2 every 3 weeks
Study: 9865705
Drug: Doxorubicin 75
Normalized name: DOXOrubicin 75 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 75 mg/m2 every 3 weeks
Study: 6295270
Drug: Ceftizoxime 2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftizoxime 2, 3, or 4 g intravenously
Study: 29595707
Drug: Naloxone (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.15 mg/kg bolus dose, then 0.2 mg/kg per hour infusion)
Study: 20079168
Drug: CT scanning
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT scanning with 16 x 1.25 mm collimation and a 70 ml contrast injection
Study: 20079168
Drug: CT with
Normalized name: Impact with Fiber
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT with 64 x 0.625 mm collimation and 20 ml of contrast injection
Study: 9620514
Drug: Ketamine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 20 mg
Study: 9620514
Drug: Alfentanil 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 2 mg
Study: 9620514
Drug: Ketamine 10
Normalized name: ketamine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 10 mg + Alfentanil 1 mg
Study: 9620514
Drug: Ketamine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 2.5 mg + Alfentanil 0.25 mg
Study: 9620514
Drug: Ketamine 5
Normalized name: ketamine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 5 mg
Study: 7695320
Drug: Amikacin once
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin once daily
Study: 7695320
Drug: Amikacin twice
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin twice daily
Study: 2785234
Drug: single-dose cardioplegia
Approvals — FDA: no, EMA: no, PMDA: no
Description: single-dose cardioplegia with a cooling jacket
Study: 562092
Drug: Diphenidol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenidol (40 mg)
Study: 562092
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 ml of 0.9% saline)
Study: 26377300
Drug: Ofatumumab maintenance
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab maintenance treatment (300 mg followed by 1000 mg 1 week later and every 8 weeks for up to 2 years)
Study: 26377300
Drug: Ofatumumab maintenance
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab maintenance treatment
Study: 21306322
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with intrathecal morphine (SA)
Study: 19254583
Drug: Rescue steroid
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue steroid group (betamethasone, 2 12‐mg doses 24 hours apart)
Study: 15046541
Drug: Fluoxetine (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (active comparator for duloxetine)
Study: 19502478
Drug: Behavioral Couples
Normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Couples Therapy (BCT)
Study: 10742638
Drug: Individual-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual-based treatment (IBT)
Study: 28050642
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one tablet)
Study: 28466022
Drug: In-plane injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-plane injection